MX347229B - Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. - Google Patents

Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.

Info

Publication number
MX347229B
MX347229B MX2014008960A MX2014008960A MX347229B MX 347229 B MX347229 B MX 347229B MX 2014008960 A MX2014008960 A MX 2014008960A MX 2014008960 A MX2014008960 A MX 2014008960A MX 347229 B MX347229 B MX 347229B
Authority
MX
Mexico
Prior art keywords
peptide
terminal fragment
calcitonin gene
modified calcitonin
amino acid
Prior art date
Application number
MX2014008960A
Other languages
English (en)
Spanish (es)
Other versions
MX2014008960A (es
Inventor
Christopher J Soares
Original Assignee
Christopher J Soares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher J Soares filed Critical Christopher J Soares
Publication of MX2014008960A publication Critical patent/MX2014008960A/es
Publication of MX347229B publication Critical patent/MX347229B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57527Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/585Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2014008960A 2012-01-26 2013-01-25 Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. MX347229B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591236P 2012-01-26 2012-01-26
PCT/US2013/023260 WO2013112912A1 (en) 2012-01-26 2013-01-25 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Publications (2)

Publication Number Publication Date
MX2014008960A MX2014008960A (es) 2015-01-16
MX347229B true MX347229B (es) 2017-04-19

Family

ID=47682066

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008960A MX347229B (es) 2012-01-26 2013-01-25 Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.

Country Status (14)

Country Link
US (3) US9193776B2 (cg-RX-API-DMAC7.html)
EP (2) EP3272769B1 (cg-RX-API-DMAC7.html)
JP (3) JP6025871B2 (cg-RX-API-DMAC7.html)
KR (2) KR102052983B1 (cg-RX-API-DMAC7.html)
CN (2) CN108997490A (cg-RX-API-DMAC7.html)
AU (2) AU2013211929B2 (cg-RX-API-DMAC7.html)
CA (1) CA2861392C (cg-RX-API-DMAC7.html)
DK (1) DK2807187T3 (cg-RX-API-DMAC7.html)
ES (2) ES2819825T3 (cg-RX-API-DMAC7.html)
IL (2) IL233655A (cg-RX-API-DMAC7.html)
MX (1) MX347229B (cg-RX-API-DMAC7.html)
NO (1) NO2864579T3 (cg-RX-API-DMAC7.html)
RU (2) RU2624016C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013112912A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997490A (zh) * 2012-01-26 2018-12-14 克里斯托弗·J·索尔斯 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途
WO2015017455A1 (en) * 2013-07-30 2015-02-05 Soares Christopher J Cgrp agonist peptides
JO3669B1 (ar) 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
CN109311959A (zh) * 2016-01-04 2019-02-05 艾得佩索拉公司 肽类似物
US11390654B2 (en) * 2016-09-02 2022-07-19 Christopher Joseph Soares Use of CGRP receptor antagonists in neuroprotection and neurological disorders
CA2967616A1 (en) * 2016-09-19 2018-03-19 The Governors Of The University Of Alberta Brain penetrant amylin receptor based peptides for alzheimer's disease
EP3707157A4 (en) * 2017-11-06 2021-08-18 Auckland Uniservices Limited PEPTIDIC CONJUGATES AS ANAGONISTS OF THE CGRP RECEIVER, THEIR PREPARATION METHODS AND THEIR USES
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214104B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
DE69332222T3 (de) 1992-06-11 2007-05-10 Alkermes Controlled Therapeutics, Inc., Cambridge Enythropoietin enthaltendes arzneimittelabgabesystem
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
BRPI0507623A (pt) * 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US7671023B2 (en) * 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
CN101208098A (zh) * 2005-03-31 2008-06-25 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
EP1954313A1 (en) * 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
EP2380592B1 (en) * 2005-11-14 2018-03-07 Teva Pharmaceuticals International GmbH Antagonist antibody directed against calcitonin gene-related peptide
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
WO2013059336A1 (en) 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
CN108997490A (zh) * 2012-01-26 2018-12-14 克里斯托弗·J·索尔斯 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途
WO2013130402A1 (en) 2012-02-27 2013-09-06 Bristol-Myers Squibb Company N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Also Published As

Publication number Publication date
RU2742826C2 (ru) 2021-02-11
AU2013211929B2 (en) 2016-05-26
JP2019006821A (ja) 2019-01-17
KR20170071613A (ko) 2017-06-23
RU2624016C2 (ru) 2017-06-30
ES2641325T3 (es) 2017-11-08
JP6025871B2 (ja) 2016-11-16
DK2807187T3 (en) 2017-09-11
AU2016205801A1 (en) 2016-08-04
US9193776B2 (en) 2015-11-24
KR101855242B1 (ko) 2018-05-09
CN108997490A (zh) 2018-12-14
EP2807187A1 (en) 2014-12-03
KR102052983B1 (ko) 2019-12-06
EP3272769A1 (en) 2018-01-24
JP2017036308A (ja) 2017-02-16
IL233655A0 (en) 2014-08-31
WO2013112912A1 (en) 2013-08-01
MX2014008960A (es) 2015-01-16
CN104271596A (zh) 2015-01-07
HK1201068A1 (en) 2015-08-21
IL252555B (en) 2020-06-30
RU2014131605A (ru) 2016-03-20
IL233655A (en) 2017-06-29
RU2017119773A3 (cg-RX-API-DMAC7.html) 2020-11-18
ES2819825T3 (es) 2021-04-19
BR112014018284A2 (pt) 2017-07-04
RU2017119773A (ru) 2018-12-06
US20170204155A1 (en) 2017-07-20
CN104271596B (zh) 2018-09-18
IL252555A0 (en) 2017-07-31
EP3272769B1 (en) 2020-06-17
US20140329752A1 (en) 2014-11-06
HK1249915A1 (en) 2018-11-16
JP6411425B2 (ja) 2018-10-24
AU2013211929A1 (en) 2014-09-11
US10370425B2 (en) 2019-08-06
KR20140132342A (ko) 2014-11-17
US20160145315A1 (en) 2016-05-26
CA2861392A1 (en) 2013-08-01
NO2864579T3 (cg-RX-API-DMAC7.html) 2018-01-20
JP2015513318A (ja) 2015-05-07
EP2807187B1 (en) 2017-07-26
CA2861392C (en) 2021-08-17

Similar Documents

Publication Publication Date Title
MX347229B (es) Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
NZ771547A (en) Gip and glp-1 co-agonist compounds
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
NZ727516A (en) Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor
UA99337C2 (ru) Жидкая лекарственная форма фсг
EA201170337A1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
PH12015500194A1 (en) Fusion proteins for treating a metabolic syndrome
BR112018076437A2 (pt) interferon porcino peguilado e seus métodos de utilização
MX345501B (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
NZ628126A (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
CA2839298C (en) Anti-inflammatory pharmaceutical products
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
JP2015513318A5 (cg-RX-API-DMAC7.html)
CL2012001656A1 (es) Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos.
EA201590329A1 (ru) Использование полученных из pedf полипептидов для стимуляции регенерации или артериогенеза в мышцах или сухожилиях
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration